ALLR קצב צמיחת רווח למניה בשנה הנוכחית allarity.com

סמל תאגידי ולוגו של allarity.com (ALLR)

The reliability of Allarity Therapeutics (ALLR) is based on the DRP AI system, which filters out ineffective therapies. The EPS percentage deviation from last year serves as practical confirmation of the trend, where the -2.60 mark is the current indicator. Development relies on partnerships with diagnostic centers, and the current course is aimed at restructuring the drug portfolio for repeat clinical trials.

צמיחת רווח למניה בשנה הנוכחית Allarity Therapeutics (ALLR): לתקופה 04.07.2022 - 17.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת allarity.com (ALLR)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח בסיסי של החברה:Allarity Therapeutics
מוצרים מיוצרים של Allarity Therapeutics

Professional capital evaluates Allarity Therapeutics (ALLR) through the lens of R&D capital expenditure efficiency. This annual earnings per share snapshot captures the trend in per-unit income over the year, reflecting the business's ability to generate value. Growth in this metric confirms the success of targeted licensing deals and fundraising efforts. The decelerating pace on the chart signals rising operating expenses for the oncology biotech. The stability of this metric determines the asset's investment reliability.